Welcome to our dedicated page for Korro Bio news (Ticker: KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.
Korro Bio, Inc. (Nasdaq: KRRO) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that develops genetic medicines using RNA editing. News about Korro often centers on the progress of its lead candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), updates from the Phase 1/2a REWRITE clinical trial, and regulatory milestones such as Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency.
Investors and observers following KRRO can expect coverage of Korro’s pipeline updates, including the nomination and advancement of KRRO-121, an RNA-editing GalNAc-conjugated candidate for hyperammonemia in urea cycle disorders and hepatic encephalopathy. Company communications also highlight its broader portfolio of GalNAc-conjugated liver-targeted programs and its efforts to apply the OPERA RNA editing platform to both rare and more prevalent diseases.
Additional Korro Bio news includes financial results, cash runway commentary, and restructuring actions such as workforce reductions intended to focus resources on clinical data generation and liver-targeted programs. The company’s collaboration and license agreement with Novo Nordisk A/S, and subsequent amendment establishing a 12‑month pause in research and development activities under that collaboration, are also key topics in recent updates.
Coverage frequently notes leadership and governance developments, including executive appointments, departures, and interim roles described in Korro’s SEC filings and press releases. For readers tracking KRRO, this news page aggregates announcements on clinical data, regulatory designations, business strategy, and corporate changes, providing a centralized view of Korro’s ongoing development as an RNA-editing biopharmaceutical company.
Korro (Nasdaq: KRRO) said CEO Ram Aiyar, Ph.D., will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026, at 11:10 a.m. ET. The event runs March 2–4, 2026, at the Boston Marriott Copley Place.
Korro (Nasdaq: KRRO) will host a virtual Analyst Day on Jan 27, 2026, 8–10 a.m. ET with management, hepatologist Bruce Scharschmidt, MD, and caregiver Michelle Dinon. Presentations will cover the unmet need in hyperammonemia, limitations of current treatments, and Korro’s development of KRRO-121, a GalNAc-conjugated construct intended to activate a biological pathway via RNA editing. The company will share preclinical data that support an anticipated regulatory filing for a first-in-human trial in H2 2026. Updates also note a GalNAc AATD program achieving >90% in vivo RNA editing and a development candidate nomination expected in H1 2026. A replay will be available for 30 days on the company website.
Korro (Nasdaq: KRRO) will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT / 1:30 p.m. ET. Ram Aiyar, Ph.D., CEO and President, will deliver the presentation; Todd Chappell, COO, and Loic Vincent, Ph.D., CSO, will also participate.
A live webcast will be available on Korro's Events & Presentations investor page at www.korrobio.com, and a replay will be accessible for 30 days following the presentation.
Korro (Nasdaq: KRRO) reported Q3 2025 results and program updates on November 12, 2025. KRRO-110 produced functional M-AAT protein in AATD patients but did not reach projected protein levels after a single dose; total AAT peaks reached ~10 µM versus a protective threshold of 11 µM. Pharmacokinetic differences between healthy volunteers and AATD patients informed a pivot to a GalNAc-conjugated construct with a potential development candidate nomination in H1 2026.
The company nominated KRRO-121 for hyperammonemia, reported $102.5M cash as of Sept 30, 2025, is cutting ~34% of its workforce, expects ~$2.4M restructuring charges, and says cash runway now extends into H2 2027. Regulatory milestones include IND clearance, Fast Track, and Orphan Drug designations.
Korro Bio (Nasdaq: KRRO) has announced its participation in six major investor and scientific conferences during September 2025. The company's leadership team, including CEO Ram Aiyar, CSO Loic Vincent, CFO Vineet Agarwal, and COO Todd Chappell, will engage in various activities across these events.
Key events include presentations at the Cantor Global Healthcare Conference and the RNA Leaders USA Congress, where they will discuss RNA editing therapies. The management team will also conduct one-on-one investor meetings at multiple conferences, including Citi's Biopharma Back to School Conference, Wells Fargo Securities Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference.
Korro Bio (NASDAQ:KRRO) reported Q2 2025 financial results and provided significant pipeline updates. The company has made substantial progress in its Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), with over 80% of planned healthy volunteers dosed and no serious adverse events observed. The company received EMA Orphan Drug Designation for KRRO-110.
Financially, Korro ended Q2 with $119.6 million in cash, reporting a net loss of $25.8 million. R&D expenses increased to $21.0 million, while collaboration revenue with Novo Nordisk reached $1.5 million. The company's current cash position is expected to fund operations into 2027.
Key upcoming milestones include an interim readout from the REWRITE trial in H2 2025, trial completion in 2026, and announcement of a new development candidate for a rare metabolic disorder by end of 2025.
Korro Bio (Nasdaq: KRRO) has received orphan drug designation from the European Medicines Agency (EMA) for KRRO-110, its investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD). This follows the FDA's orphan drug designation granted in March 2025.
KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study, with an interim readout expected in H2 2025. The EMA designation provides significant benefits, including protocol assistance, reduced fees, and market exclusivity upon approval, and is granted to medicines treating conditions affecting fewer than 5 in 10,000 people in the EU.
Korro Bio (NASDAQ: KRRO) has announced its management team's participation in three major upcoming healthcare investor conferences in May and June 2025. CEO and President Ram Aiyar, Ph.D., will lead a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21. Both Dr. Aiyar and Chief Medical Officer Kemi Olugemo, M.D., FAAN, will present at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9.
The RBC fireside chat will be available via webcast on Korro's website, with a replay accessible for 30 days following the event.
Korro Bio (NASDAQ: KRRO) reported its Q1 2025 financial results and provided key business updates. The company announced a 20% workforce reduction and operational streamlining to extend cash runway into 2027, with expected one-time restructuring charges of $1.2 million. The company ended Q1 with $139.0 million in cash.
Key financial metrics include $2.6 million in collaboration revenue, R&D expenses of $19.7 million (up from $13.6M), and a net loss of $23.4 million. The company strengthened its leadership team with appointments of Loïc Vincent as CSO and GaoZhong Zhu as SVP of CMC.
Korro remains on track for an interim readout from Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency in H2 2025, with trial completion expected in 2026. The company continues executing its 3-2-1 strategy through 2027 and plans to announce a second development candidate in 2025.
Korro Bio (NASDAQ: KRRO), a clinical-stage biopharmaceutical company developing RNA-editing genetic medicines, has announced key leadership appointments. Loïc Vincent, Ph.D. joins as Chief Scientific Officer, bringing over 20 years of drug discovery experience and a track record of advancing more than 20 drugs into clinical development.
The company also appointed GaoZhong Zhu, Ph.D. as Senior Vice President of CMC & Technical Operations, leveraging his 25+ years of pharmaceutical development experience. Additionally, Oliver Dolan was promoted to Principal Accounting Officer.
Korro is currently conducting the Phase 1/2a REWRITE clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. The company's RNA-editing platform aims to develop treatments for both rare and highly prevalent diseases.